LY3039478 + gemcitabine + carboplatin

LY3039478 + gemcitabine + carboplatin is an investigational combination therapy for advanced or metastatic solid tumors. LY3039478 (crenigacestat) is a selective, potent oral small molecule inhibitor of the Notch signaling pathway, which operates by inhibiting gamma-secretase-mediated cleavage of Notch receptors, thereby reducing aberrant Notch signaling implicated in multiple cancers. Gemcitabine is a nucleoside analog antimetabolite that inhibits DNA synthesis, and carboplatin is a platinum-based chemotherapeutic that induces DNA cross-linking and apoptosis in cancer cells. This combination is being studied primarily for its synergistic effects, leveraging LY3039478’s ability to sensitize tumor cells to DNA-damaging agents such as gemcitabine and carboplatin, particularly in tumors with Notch pathway alterations.

Other names

crenigacestat + gemcitabine + carboplatin